The invention relates to devices and methods for transporting fluid to or from a treatment site of a patient's body.
Many medical procedures benefit from transporting fluid to or from a treatment site of a patient's body. Devices for transporting fluid in a medical procedure are generally referred to as catheters. They may be used to provide drainage or administer treatment fluids. For example, catheters may be used to drain fluids from organs or from areas of abnormal fluid collection such as in a surgical wound following a surgical procedure. Catheters may also be used to deliver fluid to a treatment site to provide a vast range of therapies from cancer treatment to nutritional supplementation. A few exemplary therapies include stimulating tissue growth, administering antibiotics, flushing away impurities, killing or halting the reproduction of cancer cells, and relieving pain.
Catheters may be used in gravity driven arrangements such as with a collection container located below the treatment site or a medication container located above the treatment site. Likewise, catheters may be used in pressurized arrangements. For example, suction may be applied to a drainage catheter to draw fluids away from the treatment site. Suction devices may include elastomeric bulbs, spring actuated bellows, electromechanical vacuum pumps, and other known medical suction devices. Pressurized fluid may also be delivered through a catheter to the treatment site. For example, fluid infusion devices may include manual syringes, elastomeric infusion devices, spring loaded infusion devices, electromechanical infusion devices, and other known infusion devices.
Typical prior catheters are linear devices having one or more openings formed along a portion of their length through which fluid passes. They often perform poorly due to an inability to drain fluids from or deliver fluids to a sufficiently large area to encompass the entire treatment site. In addition, tissue folds and tissue apposition further affect the movement and collection of fluid making it difficult for prior catheters to adequately address the treatment site.
For example, where a treatment site encompasses a two or three dimensional treatment area, prior drainage catheters are only able to drain fluid from a relatively small, linear portion of the treatment area often leaving behind pockets of fluid.
Similarly, prior infusion catheters only deliver treatment fluid to a relatively small, linear portion of the treatment site leaving much of the site untreated. Prior infusion catheters may also deliver too much treatment fluid to a relatively small area resulting in pooling of treatment fluid or contact with non-target tissues. For example, infusion catheters may be used to deliver pain relieving medication directly to a surgical site to provide, for example, post-operative relief of pain resulting from a surgical intervention. If, for example, the medication does not reach tissue disrupted during the surgical intervention, it may not relieve the pain. Alternatively, if the anesthetic is delivered indiscriminately, undesired interactions may occur with local structures such as, for example, spinal nerves or vital organs.
Aspects of the invention provide devices and methods to conduct fluid away from or deliver fluid to an area of a treatment site of a patient's body. Fluid delivered to a treatment site will be referred to as treatment fluid and may be any material delivered to the treatment site to obtain a desired effect. For example treatment fluid may be water, saline, antibiotics, antiviral agents, hormones, growth factors, anti-inflammatories, analgesics, anesthetics, and/or any other material useful in treating a patient. For example, anesthetics may include marcaine, rupivicaine, bupivacaine, and/or any other anesthetic or combinations thereof.
The devices and methods of the illustrative examples maybe used in a variety of patient interventions. For example they may be used to deliver fluids to or remove fluids from a surgical site. For example they may be used to deliver medications to remove post-operative pain or drain fluids from a post-operative wound. Examples of such surgical procedures include surgery of the head, neck, chest, back, abdomen, and the extremities. Examples include general surgery, cosmetic surgery, joint surgery, and spine surgery. However, it will be apparent to one having skill in the art that the disclosed devices and methods may be used to treat a variety of other conditions by drainage of fluids from and delivery of fluids to a treatment site.
In one aspect of the invention, a catheter includes a first or connection end and an opposite, second or terminal end. A fluid conduit extends between the connection end and the terminal end for passing fluids. The terminal end includes a fluid exchange portion. The fluid exchange portion may include a hollow body having a wall defining the terminal end of the fluid conduit and one or more openings formed through the wall for passage of fluid between the fluid conduit and an exterior of the conduit. The catheter may include more than one fluid conduit. Multiple fluid conduits may provide the same or different functions. For example, the catheter may have one or more infusion conduits to conduct treatment fluid to a treatment site and one or more aspiration conduits to conduct fluids away from a treatment site. Infusion and aspiration conduits may be incorporated in the same catheter or they may be provided in separate catheters placed independently at a treatment site.
Conduits may be made of any suitable biocompatible material. For example, conduits may be made of a biocompatible polymer. For example, conduits may be made of a heat settable elastic polymer. For example, the conduit may be made of or contain a thermoplastic elastomer such as a styrenic block copolymer, polyolefin, thermoplastic polyurethane, thermoplastic copolyester, thermoplastic polyamide, and/or their various blends. For example, the conduit may contain or be made of a polyether block amide or PEBA. PEBA is available from Arkema under the tradename of PEBAX®.
The terminal end may include a diffuser having an outer surface. The diffuser may include a plurality of independent channels able to transport fluid between the conduit and discrete portions of the outer surface. The diffuser may include a network of interconnected pores able to distribute fluid throughout the diffuser and the outer surface. The diffuser may be permanently secured to the terminal end or removably secured to the terminal end. The diffuser may be placed separately at the treatment site independent of the terminal end. A separately placed diffuser may wick fluid to or from an area defined by an exterior surface of the diffuser. The diffuser may be resorbable or durable. The diffuser may be made of polymers, ceramics, metals, plant tissue, animal tissue, and/or other suitable materials. The diffuser may include fibers, fabric, sponge, textures and/or other suitable diffusing structures. For example, the diffuser may include a textured surface. The surface may be textured by stamping, knurling, roughening, and/or by other suitable means. The surface may also be textured by forming raised lines, bumps, ridges, and/or other suitable features. The texture may include fibers. The diffuser may include a network of fibers able to conduct fluid within, along, or between the fibers. The fibers may be adhered to a surface or free standing. For example, the network may be made by weaving, knitting, braiding, felting, bonding, and/or other suitable textile process. For example, the diffuser may include a fabric made of woven synthetic fibers in a generally planar arrangement and positionable between opposing tissues to transport fluid over an extended area by wicking fluid along and between the fibers via capillary action.
The terminal end may include a barrier to fluid flow to impede fluid flow in specific predetermined directions. The barrier may be connected to the one or more conduits to bias fluid flow in a preferential direction or to impede fluid flow in a non-preferential direction. The barrier may be permanently secured to the terminal end or removably secured to the terminal end. The barrier may be separate from the terminal end and placed relative to the terminal end to isolate selected portions of the patient's anatomy from the fluid flow. The barrier may, for example, impede fluid flow by juxtaposition of a fluid impervious structure and/or by absorption of fluid. The barrier may be made resorbable or durable. The barrier may be made of polymers, ceramics, metals, plant tissue, animal tissue, and/or other suitable materials. The barrier may be in the form of a block, sheet, film, layer, and/or other suitable form adapted or adaptable to the anatomic site where the barrier function is desired. The barrier may be provided pre-shaped and sized for a particular application and/or it may permit intraoperative shaping and sizing by the user. For example, the barrier may be made of a thin polymer film. In another example, the barrier may be made of collagen forming a relatively fluid impervious membrane. The barrier may be coupled to a diffuser to provide fluid flow through portions of the diffuser while blocking fluid flow through other portions of the diffuser.
The barrier and/or diffuser may separate tissue layers at the treatment site and maintain fluid communication between the tissue layers over a two-dimensional or three-dimensional treatment site to extend the effective treatment area. Furthermore, the barrier and/or diffuser may extend peripherally into the tissue folds and irregularities to separate tissue layers and enhance fluid transport between the layers and adjacent the barrier and/or diffuser. Enhancement of fluid transport reduces the number of catheters required to transport fluid to and/or away from the treatment site.
The one or more openings in the wall of the conduit may be positioned at any circumferential position around the wall. They may be placed parallel to the plane of the non-linear path of the terminal end so that they open within the space between tissue layers to avoid blocking of the openings by overlying tissue.
The barrier and/or diffuser may have a predetermined shaped that conforms to the margins of a particular surgical site. The shape may be polygonal, ovoid, spiral, or random shaped.
The terminal end of the catheter may have a first configuration and a second configuration into which it may be modified. For example, the terminal end may have a deployed configuration for fluid transport to or from a treatment site and a delivery or removal configuration. The delivery or removal configuration may be smaller than the deployed configuration to ease placement or removal of the terminal end at a desired location of a patient's anatomy. For example, the delivery or removal configuration may be folded, rolled, collapsed, stretched, compressed, twisted, deflated, straightened and/or otherwise manipulated relative to the deployed configuration.
The catheter may be placed at the treatment site in an inside-out placement method in which it is placed in an open wound and the connection end is passed out of the patient's body leaving the terminal end at the treatment site. Alternatively, the catheter may be placed at the treatment site in an outside-in placement method in which the terminal end is introduced from outside the patient's body to the treatment site. Where a surgical incision is present near the treatment site, the catheter may extend through the incision. Alternatively, the catheter may extend through another opening, such as a stab incision, formed for the purpose of passing a portion of the catheter.
Various examples of the present invention will be discussed with reference to the appended drawings. These drawings depict only illustrative examples of the invention and are not to be considered limiting of its scope.
An optional fluid impermeable barrier 120 may be positioned on one or more surfaces of the diffuser body 102 to prevent fluid transport through the portion of the diffuser body 102 covered by the barrier. Selection of the diffuser shape, infusion conduit position and flow rate, aspiration conduit position and flow rate, and/or location of fluid barriers permits the treatment fluid delivery properties of the terminal end 100 to be tailored. In the illustrative example of
While four fluid conduits 204-210 have been shown, it is to be understood that any number of conduits may be used. Furthermore, while tubular conduits have been depicted, conduits having any cross-sectional shape may be used including, for example, polygonal, curved, annular, and other cross-sectional shapes.
During delivery, the terminal end 200 can be folded and/or rolled into a small delivery configuration, not shown, and placed at the treatment site. The terminal end is then released whereupon the delivery conduits will tend to spring away from one another, as permitted by the surrounding tissue, into the configuration shown in
A barrier 326 is attached to the outer surface 312 of the elongated body 308 adjacent the aspiration openings 318. In the illustrative example of
A diffuser 330 is attached to the outer surface 312 of the elongated body 308 opposite the barrier 326. In the illustrative example of
The infusion side 304 of the terminal end 300 infuses treatment fluid into a treatment site while the aspiration side 306 aspirates fluid away from a treatment site. The barrier 326 prevents fluid flow directly from the infusion openings 324 to the aspiration openings 318. The barrier 326 also isolates patient tissues on the aspiration side 306 from treatment fluid delivered by the infusion side 304.
In the illustrative example of
The embodiment of
A treatment kit may be provided including one or more catheters according to various aspects of the invention. Optionally, the kit may include a diffuser. Optionally, the kit may include a protective barrier that may be placed separately from the catheter to shield specific tissues. Optionally the kit may include an infusion pump.
In describing aspects of the invention, various examples have been described. It is to be understood that the features from one example may be incorporated into other examples.
This application is a continuation-in-part of U.S. patent application Ser. No. 12/667,870, filed Jul. 2, 2008, herein incorporated by reference. This application claims the benefit of U.S. Provisional Application No. 61/385,309, filed Sep. 22, 2010; U.S. Provisional Application No. 61/450,096, filed Mar. 7, 2011; and U.S. Provisional Application No. 61/494,822, filed Jun. 8, 2011, each of which is herein incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3572340 | Lloyd | Mar 1971 | A |
3823720 | Tribble | Jul 1974 | A |
3854477 | Smith | Dec 1974 | A |
3967728 | Gordon et al. | Jul 1976 | A |
4048996 | Mittleman et al. | Sep 1977 | A |
4364394 | Wilkinson | Dec 1982 | A |
4445897 | Ekbladh et al. | May 1984 | A |
4623329 | Drobish | Nov 1986 | A |
4643716 | Drach | Feb 1987 | A |
4692153 | Berlin et al. | Sep 1987 | A |
D294639 | Croll | Mar 1988 | S |
4786500 | Wong | Nov 1988 | A |
D300947 | Utas-Sjoberg | May 1989 | S |
4925452 | Melinyshyn et al. | May 1990 | A |
5034006 | Hosoda et al. | Jul 1991 | A |
5100395 | Rosenberg | Mar 1992 | A |
5120304 | Sasaki | Jun 1992 | A |
5201723 | Quinn | Apr 1993 | A |
5221255 | Mahurkar et al. | Jun 1993 | A |
5234406 | Drasner et al. | Aug 1993 | A |
5318517 | Reiman | Jun 1994 | A |
5320599 | Griep et al. | Jun 1994 | A |
5324518 | Orth et al. | Jun 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5425723 | Wang | Jun 1995 | A |
5433713 | Trotta | Jul 1995 | A |
5458582 | Nakao et al. | Oct 1995 | A |
5458631 | Xavier | Oct 1995 | A |
5523092 | Hanson et al. | Jun 1996 | A |
5533986 | Mottola et al. | Jul 1996 | A |
5545151 | O'Connor | Aug 1996 | A |
5549603 | Feiring | Aug 1996 | A |
5616121 | McKay et al. | Apr 1997 | A |
5647859 | Lampropoulos et al. | Jul 1997 | A |
5647860 | Roth et al. | Jul 1997 | A |
5665076 | Roth et al. | Sep 1997 | A |
5681274 | Perkins et al. | Oct 1997 | A |
5702372 | Nelson | Dec 1997 | A |
5785678 | Griep et al. | Jul 1998 | A |
5873865 | Horzewski et al. | Feb 1999 | A |
6017323 | Chee | Jan 2000 | A |
6117125 | Rothbarth et al. | Sep 2000 | A |
6179816 | Mottola et al. | Jan 2001 | B1 |
6193704 | Winters | Feb 2001 | B1 |
6235009 | Skow | May 2001 | B1 |
6325788 | McKay | Dec 2001 | B1 |
6350253 | Deniega et al. | Feb 2002 | B1 |
6514517 | Jamiolkowski et al. | Feb 2003 | B2 |
6524300 | Meglin | Feb 2003 | B2 |
6534559 | Vanderlaan et al. | Mar 2003 | B1 |
6558686 | Darouiche | May 2003 | B1 |
6569839 | McKay | May 2003 | B1 |
6626885 | Massengale | Sep 2003 | B2 |
6676643 | Brushey | Jan 2004 | B2 |
6689110 | Brushey | Feb 2004 | B2 |
6749580 | Work et al. | Jun 2004 | B2 |
D499017 | Nestenborg | Nov 2004 | S |
D499643 | Nestenborg | Dec 2004 | S |
6878128 | MacMahon et al. | Apr 2005 | B2 |
D505067 | Nestenborg | May 2005 | S |
6893414 | Goble et al. | May 2005 | B2 |
6921541 | Chasin et al. | Jul 2005 | B2 |
7001371 | McLaughlin et al. | Feb 2006 | B1 |
7004923 | Deniega et al. | Feb 2006 | B2 |
7100771 | Massengale et al. | Sep 2006 | B2 |
7119062 | Alvis et al. | Oct 2006 | B1 |
7186247 | Ujhelyi et al. | Mar 2007 | B2 |
7195624 | Lockwood et al. | Mar 2007 | B2 |
7201745 | DiMatteo et al. | Apr 2007 | B2 |
7232425 | Sorenson et al. | Jun 2007 | B2 |
7282214 | Willcox et al. | Oct 2007 | B2 |
7326196 | Olsen et al. | Feb 2008 | B2 |
7438711 | Deniega et al. | Oct 2008 | B2 |
7452353 | Dal Porto et al. | Nov 2008 | B2 |
7462165 | Ding et al. | Dec 2008 | B2 |
7462177 | Brushey et al. | Dec 2008 | B2 |
7465291 | Massengale | Dec 2008 | B2 |
7510077 | Massengale et al. | Mar 2009 | B2 |
7510550 | Deniega et al. | Mar 2009 | B2 |
7527609 | Deniega et al. | May 2009 | B2 |
7534224 | Triebes et al. | May 2009 | B2 |
7547302 | Porto et al. | Jun 2009 | B2 |
7569045 | Deniega et al. | Aug 2009 | B2 |
7575593 | Rea et al. | Aug 2009 | B2 |
D605757 | Sawyer | Dec 2009 | S |
D605758 | Schwartz et al. | Dec 2009 | S |
7625337 | Campbell et al. | Dec 2009 | B2 |
7699830 | Martin | Apr 2010 | B2 |
7778852 | Vasko et al. | Aug 2010 | B2 |
7780638 | Deniega et al. | Aug 2010 | B1 |
7806869 | Nilsson et al. | Oct 2010 | B2 |
7815604 | Massengale et al. | Oct 2010 | B2 |
7828790 | Griffin | Nov 2010 | B2 |
7854730 | Dal Porto et al. | Dec 2010 | B2 |
7854732 | Massengale et al. | Dec 2010 | B2 |
7942864 | Hynes | May 2011 | B2 |
D640787 | Chia et al. | Jun 2011 | S |
7959623 | Massengale | Jun 2011 | B2 |
8157759 | Castillejos | Apr 2012 | B2 |
8216176 | Randolph | Jul 2012 | B2 |
20020007204 | Goode | Jan 2002 | A1 |
20020017296 | Hickle | Feb 2002 | A1 |
20020082547 | Deniega et al. | Jun 2002 | A1 |
20020177803 | Chappuis | Nov 2002 | A1 |
20030009095 | Skarda | Jan 2003 | A1 |
20030069541 | Gillis et al. | Apr 2003 | A1 |
20030069551 | Bradley, III et al. | Apr 2003 | A1 |
20030105511 | Welsh et al. | Jun 2003 | A1 |
20030181864 | Deniega et al. | Sep 2003 | A1 |
20040030281 | Goble et al. | Feb 2004 | A1 |
20040054338 | Bybordi et al. | Mar 2004 | A1 |
20040073194 | Olsen et al. | Apr 2004 | A1 |
20040193262 | Shadduck | Sep 2004 | A1 |
20050085769 | MacMahon et al. | Apr 2005 | A1 |
20050119652 | Vetter et al. | Jun 2005 | A1 |
20050177118 | Hoganson et al. | Aug 2005 | A1 |
20050192638 | Gelfand et al. | Sep 2005 | A1 |
20050272697 | Herzberg et al. | Dec 2005 | A1 |
20060015089 | Meglin et al. | Jan 2006 | A1 |
20060058731 | Burnett et al. | Mar 2006 | A1 |
20060184098 | Barnitz | Aug 2006 | A1 |
20060195059 | Freyman et al. | Aug 2006 | A1 |
20060229573 | Lamborne | Oct 2006 | A1 |
20060229586 | Faries, Jr. | Oct 2006 | A1 |
20070005004 | Hynes | Jan 2007 | A1 |
20070010786 | Casey et al. | Jan 2007 | A1 |
20070049999 | Esch et al. | Mar 2007 | A1 |
20070073239 | Skansen et al. | Mar 2007 | A1 |
20070106247 | Burnett et al. | May 2007 | A1 |
20070118096 | Smith et al. | May 2007 | A1 |
20070197959 | Panotopoulos | Aug 2007 | A1 |
20070197970 | Shen-Gunther | Aug 2007 | A1 |
20070219488 | Francescatti | Sep 2007 | A1 |
20080033324 | Cornet et al. | Feb 2008 | A1 |
20080045883 | Radojicic | Feb 2008 | A1 |
20080119802 | Riesinger | May 2008 | A1 |
20090182304 | Deniega et al. | Jul 2009 | A1 |
20090184026 | Massengale et al. | Jul 2009 | A1 |
20100000666 | Deniega et al. | Jan 2010 | A1 |
20100222668 | Dalke | Sep 2010 | A1 |
20110137267 | Phillips et al. | Jun 2011 | A1 |
20120330295 | Manwaring et al. | Dec 2012 | A1 |
Number | Date | Country |
---|---|---|
09-108218 | Apr 1997 | JP |
11-319103 | Nov 1999 | JP |
08-538960 | Nov 2008 | JP |
8001139 | Jun 1980 | WO |
WO9208514 | May 1992 | WO |
WO9517918 | Jul 1995 | WO |
WO9630064 | Oct 1996 | WO |
WO9640325 | Dec 1996 | WO |
WO9734655 | Sep 1997 | WO |
WO9818510 | May 1998 | WO |
WO0015277 | Mar 2000 | WO |
WO0105210 | Jan 2001 | WO |
WO0132068 | May 2001 | WO |
WO0170322 | Sep 2001 | WO |
WO2004101052 | Nov 2004 | WO |
WO2004101052 | Jun 2005 | WO |
WO2005110521 | Nov 2005 | WO |
2006114637 | Nov 2006 | WO |
2006114638 | Nov 2006 | WO |
WO2007070096 | Jun 2007 | WO |
WO2007142688 | Dec 2007 | WO |
WO2007143179 | Dec 2007 | WO |
WO2009009367 | Jan 2009 | WO |
WO2009009367 | Jan 2009 | WO |
WO2012040311 | Mar 2012 | WO |
Entry |
---|
Prior, David V., “Localised Drug Delivery via Collagen-Based Biodegradable Matrices,” The Drug Delivery Companies Report Autumn/Winter 2004, pp. 39-42. |
Innocoll, Inc., “Files US and Irish Patent Applications for its CollaRx® Bupivacaine Implant for the Management of Post-operative Pain,” Mar. 29, 2007 10:49:32 AM, from http://www.innocollinc.com/. |
Supplementary European Search Report for European patent application No. 08781266.5, dated Jun. 16, 2011, 9 pages. |
International Preliminary Report on Patentability, for International application No. PCT/US2008/068998, dated Jan. 12, 2010, 1 page. |
International Search Report for International application No. PCT/US2008/068998, dated Feb. 25, 2009, 3 pages. |
International Search Report for International application No. PCT/US2011/052524, dated Apr. 27, 2012, 6 pages. |
English Abstract of JP 11-319103, dated Nov. 24, 1999, 1 pp. |
Number | Date | Country | |
---|---|---|---|
20120078220 A1 | Mar 2012 | US |
Number | Date | Country | |
---|---|---|---|
61385309 | Sep 2010 | US | |
61450096 | Mar 2011 | US | |
61494822 | Jun 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12667870 | Feb 2011 | US |
Child | 13240781 | US |